SS-31
SS-31: Elamipretide, a mitochondria-targeting peptide associated with cardiolipin.
What is it?
Elamipretide, a mitochondria-targeting peptide associated with cardiolipin.
How it is studied
It interacts with cardiolipin in the inner mitochondrial membrane. Studies investigate mitochondrial structure, energy production, and disease-specific outcomes.
What the evidence says
The FDA approved the specific medicine Forzinity on September 19, 2025, to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. Its evidence came from a small clinical programme with an extension study.
What remains uncertain
This narrow approval does not apply to general longevity claims or the SS-31 research vial listed here. A regulated medicine and a laboratory reagent are not interchangeable.
Sources & scope
FDA drug-trial snapshot: Forzinity
For in-vitro laboratory research only. Not for human or veterinary use.